Jinghao Medical 锦好医疗
17 significant filings since 30 May 2026: 8 on buyback, 5 on equity incentive and 2 on change of interest, and 2 other kinds. The latest, on 17 Sep 2026: 限制性股票激励计划限制性股票解除限售公告. On 25 Aug 2026 the company said it expects net profit for the period ending 30 Sep 2026 to change by an amount it did not state from the same period a year earlier.
自 30 May 2026 起有 17 份重大公告：buyback 8 份、equity incentive 5 份、change of interest 2 份，另有 2 类。最新一份（17 Sep 2026）：限制性股票激励计划限制性股票解除限售公告。25 Aug 2026 公司预告截至 30 Sep 2026 的净利润较上年同期变动幅度未披露。
As of 25 Sep 2026 截至2026年9月25日
Jinghao Medical is a medical device company listed on the Beijing Stock Exchange since 25 Oct 2021. The company reported strong growth in 2025, with revenue rising to RMB307.5m and attributable net profit increasing to RMB15.4m, up 65.3% and 157.0% respectively from 2024. Profit quality improved, with operating cash flow per share at RMB0.17 and a cash flow to net profit ratio of 1.11x. However, the first half of 2026 showed a reversal, with revenue down 6.8% and a net loss of RMB6.0m, marking a shift from profit to loss. The share price has declined sharply, falling 64.0% over one year, which has triggered a risk flag. The company maintains a healthy balance sheet with a low liabilities to assets ratio of 15.8% and strong liquidity ratios as of 30 Jun 2026.
锦好医疗是一家医疗器械公司，于2021年10月25日在北京证券交易所上市。公司2025年业绩表现强劲，营业收入达3.08亿元，归母净利润达1,535.9万元，同比分别增长65.3%和157.0%。盈利质量改善，每股经营现金流为0.17元，经营现金流与净利润之比达1.11倍。但2026年上半年出现逆转，营业收入同比下降6.8%，归母净利润亏损597.6万元，由盈转亏。股价在过去一年下跌64.0%，触发风险警示。截至2026年6月30日，公司资产负债率为15.8%，流动比率和速动比率良好，财务结构稳健。
| Flag 标记 | Risk 风险 | Mechanism 影响机制 |
|---|---|---|
| Share price down 40% or more in a year 股价一年下跌40%或以上 | The share price has declined by 64.0% over one year. 股价在过去一年下跌了64.0%。 | A sharp and sustained share price decline may reduce investor confidence and market valuation, potentially limiting access to equity financing. It may also affect shareholder sentiment and increase volatility. 股价大幅持续下跌可能削弱投资者信心和市场估值，限制股权融资能力，还可能影响股东情绪并加剧股价波动。 |
- Change in attributable net profit for the full year 2026 compared to 2025.
2026全年归母净利润相较于2025年的变动情况。 - Revenue trend in the next reported period after H1 2026.
2026年上半年之后下一个报告期的收入走势。 - Operating cash flow per share in the 2026 full-year report.
2026全年报告中的每股经营现金流。 - Liabilities to assets ratio at the end of 2026.
2026年末的资产负债率。 - Whether the net loss in the period to 30 Jun 2026 narrows or widens in the next period compared to the same period a year earlier.
截至2026年6月30日的报告期净亏损在下一期间相较于去年同期是否收窄或扩大。 - Gross margin level in the next reported period.
下一报告期的毛利率水平。
- Company: Jinghao Medical 锦好医疗, Beijing Stock Exchange 920925; industry Medical Devices; listed 25 Oct 2021.
公司：锦好医疗，北京证券交易所 920925；行业：医疗器械；上市日期：2021年10月25日。 - Close on 24 Sep 2026 RMB11.16; close on 24 Sep 2025 RMB31.15, RMB31.01 in today's terms; one-year change, adjusted for distributions and share changes -64.0%.
2026年9月24日收盘价11.16元；2025年9月24日收盘价31.15元（前复权31.01元）；一年涨跌幅（复权）-64.0%。 - 52-week range in today's terms, adjusted for distributions and share changes RMB10.21 to RMB38.06.
52周区间（前复权）10.21元至38.06元。 - In the last 12 months 9 trading days closed 9% or more above or below the day before (all days, not only this year). The 5 most recent of them: 6 Jan 2026 -14.6%; 7 Jan 2026 -14.8%; 10 Jul 2026 +10.1%; 21 Jul 2026 +11.9%; 24 Jul 2026 -11.0%. The longest run of them on consecutive trading days: 3 days.
近12个月共有9个交易日收盘涨跌幅达9%及以上（为全部交易日，不限于今年）。其中最近5个：2026年1月6日 -14.6%；2026年1月7日 -14.8%；2026年7月10日 +10.1%；2026年7月21日 +11.9%；2026年7月24日 -11.0%。其中最长连续3个交易日。 - Market capitalisation RMB1.10bn; P/E TTM 658.0; price to book 3.02x.
总市值11.00亿元；市盈率（TTM）658.0；市净率3.02倍。 - Revenue 2025 RMB307.5m; 2024 RMB186.1m; change +65.3%.
营业收入2025年3.08亿元；2024年1.86亿元；同比+65.3%。 - Attributable net profit 2025 RMB15.4m; 2024 RMB6.0m; change +157.0%.
归属于母公司股东的净利润2025年1,535.9万元；2024年597.6万元；同比+157.0%。 - Net profit excluding non-recurring items, 2025 change +253.1%.
2025年扣除非经常性损益后的净利润同比+253.1%。 - Basic EPS 2025 RMB0.16; 2024 RMB0.06.
基本每股收益2025年0.16元；2024年0.06元。 - Operating cash flow per share 2025 RMB0.17; 2024 -RMB0.07; operating cash flow to net profit 1.11x.
每股经营现金流2025年0.17元；2024年-0.07元；经营现金流与净利润之比1.11倍。 - 2025 gross margin 37.6%; net margin 4.8%; ROE 4.2%.
2025年毛利率37.6%；净利率4.8%；净资产收益率4.2%。 - At 30 Jun 2026: liabilities to assets 15.8%; current ratio 3.33; quick ratio 2.32; receivable days 36; inventory days 202.
截至2026年6月30日：资产负债率15.8%；流动比率3.33；速动比率2.32；应收账款周转天数36；存货周转天数202。 - Period to 30 Jun 2026 (six months, not comparable with the full years above): revenue RMB105.7m, change -6.8%; attributable net profit -RMB6.0m, change -177.5% (from a profit to a loss); operating cash flow per share RMB0.05.
截至2026年6月30日的报告期（六个月，不可与上述全年数据直接比较）：营业收入1.06亿元，同比-6.8%；归母净利润-597.6万元，同比-177.5%（由盈转亏）；每股经营现金流0.05元。 - Ownership: actual controller 王敏,王芳; controlling shareholder 王敏; largest holder at 24 Aug 2026: 王敏, 25.71%.
股权：实际控制人：王敏,王芳；控股股东：王敏；2026年8月24日第一大股东：王敏，持股25.71%。 - Latest distribution: ex-date 16 Jul 2026, cash RMB0.05 per share.
最近一次分配：除权除息日2026年7月16日，每股现金0.05元。 - Aurelian Grade D, score 31.6 of 100, graded within a peer group of 140 companies in its industry; no rank among peers is given.
金源评级D，得分31.6（满分100），于行业同业140家中评定；未提供其在同业中的排名。 - Not held for this report: receivable ageing, litigation case amounts, the order book, the auditor's opinion and key audit matters, segment revenue.
本报告未掌握：应收账款账龄、诉讼案件金额、在手订单、审计意见及关键审计事项、分部收入。